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Table 1 e Salient features of the coronary artery disease
(CAD) epidemic in India. India topped the world with 1,531,534 cardiovascular disease-
related deaths in 2002.2
 Incidence of CAD in young Indians is about 12%e16%, which is
higher than any other ethnic group.2
 According to the INTERHEART study, median age of first heart
attack in Indians is 53 years whereas that in Western Europe,
China, and Hong Kong is 63 years, with more men affected than
women.3
 Half of the CVD-related deaths (i.e., 52% of CVDs) in India occur
below the age of 50 years, and about 25% of acute myocardial
infarction (AMI) in India occurs below the age of 40 years.2
 Age-standardized estimates for disability-adjusted life-years lost
due to CAD per 1000 population in India are three times higher
than in developed countries.2Cardiovascular disorders are the major cause of morbidity &
mortality globally as well in India. In 2008, out of the 57million
deaths globally; around 63% (i.e., nearly 30 million deaths)
were due to non-communicable diseases.1 Cardiovascular
diseases accounts for nearly half of the deaths due to non-
communicable diseases worldwide, thus becoming the lead-
ing cause of death due to non-communicable diseases.
Approximately, 80% of these deaths have been reported to
occur in low and middle-income countries.1
Moreover, out of nine million premature deaths due to
non-communicable diseases (viz. age< 60 years); around eight
million occurred in low and middle-income countries. With
6.8% and 5.0% of disability-adjusted life-years (DALYs) lost,
CAD is the second largest causes of disease burden in popu-
lation aged 15 years and older globally.11.1. Trends of cardiovascular diseases in India
Cardiovascular diseases have assumedepidemic proportions in
India as well. The Global Burden of Diseases (GBD) study re-
ported the estimated mortality from coronary heart disease
(CHD) in India to be 1.6 million in the year 2000 which is esti-
mated to increase to w64 million by the year 2015.2 The pro-
jected rise in disease burden due to CVD is expected to make it
the prime contributor of total mortality and morbidity.2
Reports on CAD in Indians have shown that Asian Indians
are at 3e4 times higher risk of CAD than white Americans, 6
times higher than Chinese, and 20 times higher than Japanese.3
Various independent epidemiological studies conducted in
North India suggest that the prevalence of CAD has increased
from 1% in 1960 to 10.5% in 1998 in the urban population.3 Ahigher prevalence of CAD, ranging from 11.0% to 14.2%, has
been reported from South India.3 Taking into account the size
of the Indian population, these prevalence rates indicate that a
large number of deaths can be attributed to CAD.3
1.2. Premature CAD in Indians
Cardiovascular diseases are characterized by early age of
onset and greater mortality in developing countries likeIndia.4 In India, the high burden of CVD is not only the prime
concern, but also the effect of CVD on productive workforce
aged between 35 and 65 years is more worrisome.5 CHD in
Indians is reported to occur a decade or two earlier than their
counterparts in developed countries.5 Since it manifests at a
younger age it can have devastating consequences for an in-
dividual, the family and society. Moreover, this being in-
dividual’s working period of life results in loss of potentially
productive years of life in India. Among working-age adults
(35e64 years old), nearly 18 million productive years of life are
expected to be lost fromCAD by 2030, a number which ismore
than nine times higher than expected in the USA.6 This
pattern of disease has substantial implications on India’s
growing workforce and economy (Table 1).61.3. A comparison of AMI scenario in India vs developed
countries.The most comprehensive data about contemporary trends
in STEMI patients come from CREATE, a large clinical registry
of acute coronary syndrome patients regularly from 89 large
hospitals in 10 regions and cities across India.7
 About 60% of patients who were assessed had STEMI,
whereas in reports from developed countries including the
European Heart Surveys, <40% had STEMI. This suggests
that patients admitted to Indian hospitals with ACS are
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countries.7
 Three-quarters of the patients were from lowermiddle class
and poor backgrounds and were less likely to be able to
afford routine treatments in hospitals and for secondary
prevention.
 Patients with STEMI took much longer to reach hospital
(median 300 min) than did patients in developed countries
(range from 140 to 170 min).7
 Patients with non-STEMI or unstable angina took even
longer to reach hospital (median 420 min). Few patients
used an ambulance to reach the hospital; most used private
or public transport.7
 The reasons patients reached hospital late include eco-
nomic reasons, a lack of awareness about the importance of
the symptoms and different types of healthcare providers
that prevent rapid access to secondary and tertiary care
hospitals.7
 Rates of primary PCI were lower while that of thrombolytic
treatment was higher than in developed countries. This is
probably because around three-fourth of patients in India
have to pay directly for their own treatments. Moreover,
around 25% of the patients had coronary angiography as
compared to 50% of the patients in developed countries.
Similarly, the rate of PCI in STEMI patients was much lower
than in developed countries.7
 The equivalent rate of PCI in patientswho had non-STEMI or
unstable angina was 7%, whereas in developed countries it
was higher (around 25%e37%).7
 The rates of coronary artery bypass graft were even lower in
our patients.7
 Although STEMI patients were about a decade younger
than those in other registries, their 30-day mortality (9%)
was higher than in developed countries (range 6e8%).
The mortality in patients with non-STEMI was 3$7%,
which was also higher than mortality in developed
countries.71.4. The current status of treatment of AMI in India
Primary angioplasty in acute myocardial infarction (PAMI) is
the gold standard treatment formanagement of AMI due to its
profound ability to achieve high percentage of reperfusion.8
Nearly all patients are eligible for PAMI and a complete eval-
uation of coronaries is possible with confirmation of the acute
occlusion. It leads to prompt revascularization under vision
with >90% TIMI 3 flow and with stent placement the residual
stenosis is eliminated.9
However, this treatment modality is available only to less
than 10% of STEMI patients in India (CREATE registry)
whereas in the developed countries where good transfer fa-
cilities exist 28% of STEMI patients receive the benefit of
PAMI. In Indian conditions, even small towns have a popu-
lation above 100,000 people.8 Moreover, lack of awareness,
inappropriate transfer facilities, traffic congestion and
consultation with family physicians are some of the factors
that delays the time to treatment. In small towns where
reaching a hospital quickly may be possible, hospital with
PAMI capabilities are not available. At the tertiary carehospital where the time from reaching the casualty to
establish TIMI 3 flow has its own delay of formalities, round
the clock availability of skilled manpower and availability of
cath lab in busy hours.8 All these situations are expected to
get worse in India in the future.8
1.5. Hurdles in PAMI. role of thrombolysis
In smaller cities of India, thrombolysis continues to be a vogue
as the facilities for primary angioplasty in myocardial infarc-
tion (PAMI) are not available and transport facilities are
limited. Also in India the ambulance facilities are poor and
those available are often not up to the mark.10 Most of the
times, patients with STEMI condition present late after the
onset of symptoms and the desired goals like, door-to-needle
time and door-to-balloon time, as specified in guidelines, are
rarely met. In CREATE registry, only 41.6% of patients with
STEMI presented within 4 h of the onset of chest pain and 31%
of patients presented after 12 h.10
Presently, there are over 500 centers with facilities for
coronary angiography in India10; however, the number is quite
disproportionate to the size of CAD patient burden in the
country. Extrapolation of the Global Burden of Diseases (GBD)
study showed that current burden of CAD in India is as high as
>32million patients with a sizeable proportion in rural (3e5%)
and urban (7e10%) population.10 Hence, in Indian conditions
with delayed access to the limited number of catheter labo-
ratories and insurance benefits being a rarity, pre-hospital or
in-hospital thrombolysis should be the treatment of choice for
patients with AMI similar to what the latest review by Kuna-
dian V. and Gibson M. concluded.11,12
Approval of third generation thrombolytics by the Drug
Controller of India (DCGI) was a major step towards devel-
oping viable STEMI systems of care in the country. These new
generation fibrinolytic drugs improve reperfusion rates and
relative clinical outcomes in STEMI patients. The ability of
third generation thrombolytics to be administered as a bolus
has made it possible to consider pre-hospital treatment
in certain settings.6 New data on adjunctive therapy with
Clopidogrel may also expand the benefits of fibrinolytic
therapy.6 Finally, an improved understanding of the role of
pharmacoinvasive approach, i.e., the combination of imme-
diate pharmacological reperfusion with invasive cardiac pro-
cedures, suggests the possibility of targeting PCI in high-risk
patients.62. Management of AMI: the current scenario
In the successful management of AMI, timely reperfusion
therapy (either pharmacologic or catheter-based) is essential
in order to rapidly restore the coronary blood flow and limit
myocardial necrosis. The optimal goal of any system is to
facilitate rapid recognition of symptoms and treatment of
patients with STEMI such that the medical contact-to-needle
(door-to-needle) time for initiation of fibrinolytic therapy is
ideally achieved within 30 min (or) the medical contact-to-
balloon (door-to-balloon) time for PCI is achieved within
90 min.13 In India, the CREATE registry reported that the me-
dian time to reach a hospital was 300 min and the proportion
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per the ACC guidelines on STEMI management, the patients
with acute MI who are suitable candidates for fibrinolytic
therapy, should be thrombolysed as soon as possible, ideally
within 30 min of first medical contact.13
In pharmacological reperfusion therapy, fibrinolytic agent
is the key component of pharmacological “cocktail” adminis-
tered for the treatment of STEMI. Fibrinolytic therapy has
been a cornerstone in treatment of patients presenting early;
however, adjunct antithrombotic agents (Anticoagulants [viz.
Heparin/Enoxaparin] and Anti-platelet drugs [viz. Aspirin,
Clopidogrel]) are of utmost importance for maximizing and
maintaining the benefit of drug dissolving the occlusive
thrombus in the Infarct Related Artery (IRA).14 The inability to
achieve microvascular reperfusion with fibrinolysis (in
around 40% of patients) and primary PCI (in around 25% of
patients) prompts the use of adjunctive therapy before and
combined with invasive strategies.15
2.1. Approaches to treatment of AMI
The absolute goal of AMI treatment is to achieve earliest
possible reperfusion.
Way back in 1980, it was demonstrated that occluding
thrombosis of a coronary artery is the most frequent cause of
AMI. Since then, a number of authors have hypothesized that
early reperfusion of the IRA may potentially limit infarct size,
preserve left ventricular function and ultimately reduce
morbidity and mortality.16
Primary PCI (angioplasty and/or stenting without prior use
of concomitant fibrinolytic therapy) is the preferred thera-
peutic option when it can be performed within 90 min after
the first medical contact. The procedure demands a high de-
gree of expertise in terms of an experienced team, which in-
cludes not only interventional cardiologists, but also skilled
supporting staff. Therefore, only the hospitals with an estab-
lished interventional cardiology programme can use primary
PCI as a routine treatment option for patients presenting with
AMI.18
The therapeutic goal in AMI is to retard coagulation and
platelet function and open the infarct related coronary artery
to achieve the greatest degree ofmyocardial reperfusion in the
shortest possible time. The clinical approaches usually avail-
able to achieve myocardial reperfusion include some combi-
nation of thrombolysis, angioplasty, anticoagulation, platelet
inhibition and b-adrenergic blockade.16
The most common approaches considered by the clini-
cians are as follows:17
 Facilitated PCI e a strategy of full- or half-dose fibrinolysis,
with or without administration of a glycoprotein (GP) IIb/IIIa
receptor antagonist, with immediate transfer for planned
PCI within 90e120 min.
 Rescue PCI refers to the transfer for PCI of patients who
demonstrate findings of failed reperfusion with fibrinolysis.
 Pharmacoinvasive strategy e the administration of fibri-
nolytic therapy either in the prehospital setting or at a non-
PCI-capable hospital, followed by immediate transfer to a
PCI-capable hospital for early coronary angiography and PCI
when appropriate.2.1.1. Primary PCI (angioplasty and/or stenting without prior
use of concomitant fibrinolytic therapy)
ACC/AHA guidelines recommend primary PCI in equipped
settings as it offers several important potential advantages
over pharmacologic reperfusion.19
2.1.1.1. Advantages of primary PCI19,20. Primary PCI is suit-
able for 90% of patients, establishes initial Thrombolysis In
Myocardial Infarction (TIMI) flow grade 3 in 70e90% of
patients.
1. Nearly eliminates the risk of intracranial hemorrhage,
2. Preferable to alternative treatments in high-risk patients,
such as those with cardiogenic shock, severe congestive
heart failure, or hemodynamic or electrical instability.
3. Appropriately selected patients undergoing primary PCI
were shown to have lower rates of nonfatal reinfarction,
stroke, and short-termmortality than fibrinolytic recipients
in a meta-analysis of data from 23 randomized trials
enrolling fibrinolytic-eligible patients with STEMI.20
The short-term and long-term clinical outcomes for the 23
trials were evaluated to compare primary percutaneous
transluminal coronary angioplasty (PTCA) with thrombolytic
therapy for acute ST-segment elevationmyocardial infarction
(AMI). Overall, patients assigned to primary PTCA were less
likely to die, have a non-fatal reinfarction, or fall within the
group who had a combined endpoint of death, non-fatal
reinfarction, and stroke, than those assigned thrombolytic
therapy. These outcomes were significantly decreased not
only in the short-term, but also over long-term follow-up.20
Hence it was concluded that Primary PTCA is more effective
than thrombolytic therapy for the treatment of ST-segment
elevation AMI.20 (See Annexure Table).
2.1.1.2. Limitations of primary PCI and place of thrombolysis in
the treatment of AMI (Indian context). Clinical studies indicate
that the speed of reperfusion after infarct onset may be more
important than whether pharmacologic or mechanical inter-
vention is used. Therefore, Primary PCI would have become the
universally dominant strategy for achieving early reperfusion if
resource and logistical constraints had not limited its broad-
based adoption. As discussed earlier, time to reperfusion is
the most critical variable in STEMI management and is partic-
ularly important for PCI. Availability of invasive facilities is
another important determinant of the feasibility of PCI.19
Unless rapid transfer to an appropriately staffed facility is
available and systems are in place to make it possible, PCI
generally involves variable delays. Door-to-balloon times of
<90 min are achieved in only approximately one-third of pa-
tients who do not require transfer and in a much smaller pro-
portion of patients presenting tohospitalswithout ready access
to primary PCI.19 Real-world data from the National Registry of
Myocardial Infarction (NRMI-3 and -4) databases (n ¼ 4278)
shows that the total door-to-balloon times of<90 and<120min
were achieved in only 4.2% and 16.2%, respectively, of STEMI
patients transferred for PCI (median 180 min).19
Because up to 70% of STEMI patients present to hospitals
without on-site PCI facilities, and prolonged door-to-balloon
times commonly limit the benefit of PCI, the continued role
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should be emphasized.19 Logistical complexities such as triage
or transportation delays must be considered when a reperfu-
sion strategy is selected, because prompt fibrinolysis may
achieve greater benefit, especially if the fibrinolytic-to-PCI
time delay associated with transfer exceeds >1 h.19
2.1.2. Thrombolytic agents
2.1.2.1. Historical perspective. Dr. William Tillett in 1933
discovered “Streptokinase” (SK) when he observed that
streptococci agglutinated with plasma but not with serum,
which is another great example of serendipity. He concluded
that any plasma containing streptococci would not clot and
this laid the foundation for thrombolysis in various settings.
In 1945, the term “streptokinase” was coined.11
Due to non-specificity, side-effects like allergic reactions
and hypotension occurred with SK. The initial description of a
prolonged infusion of SK for patients with AMI appeared in
1958, followed by several smaller studies, but no definitive
benefit was discernible until a meta-analysis of these early
studies suggested a significant mortality benefit with first
generation fibrinolytics. It was soon recognized that intra-
coronary fibrinolytic therapy could salvage jeopardized
ischemic myocardium, and that early restoration of patency
of the IRA resulted in better preserved left ventricular func-
tion. Thereafter, a significant mortality benefit with IV fibri-
nolysis was demonstrated and confirmed. This has led to
worldwide adoption of IV fibrinolysis for acute STEMI.12 Since,
SK is derived from streptococcus source and is non-fibrin
specific in nature, various side effects like systemic bleeding
complications, allergic reactions and hypotension occur with
streptokinase. To address these issues, the newer fibrinolytic
agents evolved subsequently.
In 1952, Macfarlane and Pilling isolated another fibrino-
lytic, “Urokinase” (UK) which unlike SK, was non-antigenic.
But since it was isolated from human urine, it was pre-
sumed that it may transmit infections.
The advent of recombinant DNA technology sparked a
revolution in biology and spurred the development of the
biotechnology industry. Recombinant technology was then
themethod of development of all thrombolytics that followed.
The first thrombolytic molecule to be developedwas Alteplase
e a recombinant form of natural tPA (a second generation
agent) that showed marked benefits in terms of safety and
efficacy profile over earlier generation drugs. However, due to
its shorter half life it has to be administered as a continuous
infusion making its administration process more complex.
Anistreplase belonging to the same class has an advantage of
a single bolus due to longer half-life. Later it was hypothesized
that genetic modification of the molecule to delete specific
domains could create an improved thrombolytic with a longer
half-life and rapid onset of action, permitting bolus adminis-
tration. Moreover, it would be capable of achieving normal
TIMI 3 flow in a large percentage of patients and would have a
lower bleeding risk. Tenecteplase and reteplase are the two
third generation fibrinolytic drugs that result from the modi-
fication of native tPA. These variations substantially
decreased their clearance from plasma resulting in longer
half-life allowing administration as a single bolus and also
conferring higher fibrin specificity. The dose is calculated onthe basis of body-weight for tenecteplase whereas for rete-
plase no weight-based dosing calculations are required.
Modifications in molecular structure of reteplase resulted in
some of the unique properties of drug including high fibrin
specificity, low fibrin affinity (binding), longer half-life and
greater thrombolytic potency in comparison to t-PA.
Fibrinolytic agents are the preferred pharmacologic class
for the management of STEMI because of their ability to ach-
ieve reperfusion and to restore blood flow when administered
within 12 h of symptomonset. Thrombolytic trials in AMI over
the past decade have shown early achievement of more rapid
patency& TIMI grade 3 flow and reduced 24-hmortality.16,21 In
the Myocardial Infarction Triage and Intervention which was
a randomized, double blind trial, by Weaver WD et al.,
administration of thrombolytic therapy within 70 min of
symptom onset, whether prehospital or in-hospital, reduced
mortality from 8.7% to 1.2% (p ¼ 0.04).22,23
Large randomized clinical trials (RCTs) as well as the
Fibrinolytic Therapy Trialists overview have clearly demon-
strated a statistically significant mortality benefit with
thrombolytic therapy over placebo in this clinical setting.12 It
demonstrated an overall risk reduction in 35 day mortality of
18% with thrombolytic treatment. The beneficial effect of
thrombolysis extends to patients presenting within 12 h of the
onset of symptoms, but it is clear that the earlier patients are
treated the better their outcome. Thrombolytic treatment
saves about 30 lives per 1000 patients presenting within 6 h of
symptom onset.24
Thrombolytics in AMI e pivotal trials
Although several small studies demonstrated the benefi-
cial effects of SK in terms of reducing 30-day and 1-year
mortality, the GISSI and the ISIS trials firmly established the
efficacy of intravenous SK in themanagement of patientswith
AMI.11
In the GISSI trial, at 21 days there was 18% reduction in
overall hospital mortality following the administration of SK
compared with the control group (p ¼ 0.0002). Likewise in
randomized trial of intravenous SK, oral aspirin, both, or
neither among cases of suspected AMI demonstrated that
streptokinase and aspirin alone give significant reduction in 5-
week vascular mortality. Also the combination was better
than either agent alone. But SK was associated with excess of
bleeds requiring transfusion, intracranial hemorrhage and
non-fatal reinfarction if used alone.25
Newer thrombolytic agents have been developed in order
to provide longer half-life to enable bolus administration,
fibrin specificity, and to be resistant to natural inhibitors such
as plasminogen activator inhibitor-1 (PAI-1). Following the
breakthrough discovery of SK in the treatment of patients
with AMI and the emergence of novel agents, the attention
shifted to determine which thrombolytic agent was the best.
The GUSTO (Global Use of Strategies to Open Occluded Coro-
nary Arteries), GISSI-2 and ISIS-3 investigators compared
intravenous SK and t-PA in the treatment of AMI.11
The GISSI-2 trial consisting of 12,490 patients demon-
strated that SK and tPA were equally safe and effective in AMI
and did not demonstrate specific differences between the two
thrombolytic agents (tPA vs. SK) with regards to the combined
endpoint of death and severe left ventricular damage (23.1%
vs. 22.5%). Althoughmajor bleedwas significantly higher in SK
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incidence of stroke was similar in all treatment groups.11
Although no significant difference was observed between SK
and tPA inGISSI-2 and ISIS-3, theGUSTO trial demonstrated that
an accelerated regimen of tPA (administration of tPA over a
period of 90 min, with two-thirds of the dose given in the first
30 min instead of the conventional period of 3 h) resulted in
significant reductions in death and disabling strokes among pa-
tientswithAMI.Accelerated tPAgroup resulted in 14% reduction
in mortality at 30 days compared with the SK strategies. There
was slight excess of hemorrhagic stroke for accelerated tPA
(p ¼ 0.03) when compared with the SK strategies. However, the
combinedendpoint of deathordisabling strokewas significantly
lower in the accelerated tPA group than in the SK only groups
(6.9%vs. 7.8%,p¼ 0.006). Thusaccelerated t-PAprovidedahigher
rate of early perfusion and a lower mortality rate.11
When the patients receiving SK as the thrombolytic agent
were evaluated within GUSTO II, a striking reduction in mor-
tality and other adverse eventswas evident. These results were
consistent with angiographic studies, which showed that a
direct thrombin inhibitor in combination with SK results in a
substantially higher rate of TIMI grade 3 flow than SK and
heparin in combination.26
The GUSTO IIb direct angioplasty sub-study was performed
to provide a broader perspective on the comparison between
direct angioplasty and thrombolysis with accelerated admin-
istration of t-PA. Though at 30 days of follow-up, the composite
endpoint favored direct PTCA (9.6% vs 13.7%; p ¼ 0.03), but by 6
months approximately half of that benefit was lost. This result
is consistent with the open artery concept that direct angio-
plasty was superior to thrombolytic therapy, although the
smaller than expected size of the difference raises questions.26
In comparison with SK, ‘standard’ alteplase and acceler-
ated alteplase administration, reteplase has been shown to
produce a higher rate of TIMI grade 3 flow at 60 and at 90 min.
This enhanced patency rate coupledwith the convenience of a
bolus administration provided an attractive approach to
thrombolysis.26
The superior results of catheter-based strategies of reper-
fusion, as compared with thrombolytic therapy, although not
entirely durable over the long term, most likely relate to the
fact that there is earlier and more complete restoration of
myocardial blood flow than occurs with thrombolytic agents.
Substantial increases in speed and persistence of reperfusion
require better adjunctive agents such as direct antithrombins,
which markedly improved the results obtained with SK, or
inhibitors of platelet glycoprotein IIb/IIIa.
The GUSTO IV ACS study indicated that glycoprotein IIb/
IIIa receptor blocker abciximab was not beneficial as first-line
medical treatment in patients admitted with acute coronary
syndromes without early coronary revascularization.27
The combination of abciximab in full doses and reteplase
in half doses did not significantly reduce the rate of mortality
at 30 days in patients with acute STEMI when compared with
reteplase in full doses in the GUSTO V trial.28
A double dose reteplase (10 þ 10 MU) utilized in the RAPID
trial resulted in complete, rapid and sustained thrombolysis of
IRA at 90min and 5e14 day (63% vs. 49%, p¼ 0.019; and 88% vs.
71%, p< 0.001) compared with alteplase and improved regional
and global left ventricular function at discharge. The RAPID IItrial further confirmed the advantage of reteplase over accel-
erated alteplase in achieving higher rates of early reperfusion
in the IRA and fewer acute coronary interventions.11
The second generation thrombolytic anistreplase was
compared in a study, where SK vs tissue plasminogen activator
vs anistreplase and aspirin plus heparin vs aspirin alone were
analysed in a randomized comparison among 41,299 cases of
suspected AMI.29 The AspirineHeparin combination versus
aspirin alone showed no significant medium-term survival
advantage, slightly fewer deaths during heparin treatment, but
may cease when heparin stops. Also no significant difference
with respect to total stroke, excess of major non-cerebral
bleeds or excess of definite or probable cerebral hemorrhage
was observed.29
Anistreplase compared to SK showed no significant dif-
ference in reinfarction, similar 6 month survival, more allergy
and slight excess strokes.29
rtPA compared to SK demonstrated no significant differ-
ence in mortality but fewer reinfarctions.29
Inaddition to theGUSTO trial, other trials demonstrated that
the accelerated alteplase infusion regimen administered over a
90-min period to be the preferred treatment strategy when
compared with a double dose alteplase therapy due to slightly
increased rate of intracranial bleeding in the latter group (1.12%
vs. 0.81%). The phase I TIMI trial demonstrated that the admin-
istration of rtPA in patients with AMI resulted in reperfusion in
twice as many occluded infarct-related arteries compared with
SK during the first 90 min of initiation of treatment.11
Another form of t-PA is the TNK mutant, which has both a
longer half-life and markedly enhanced fibrin specificity.
Angiographic trials had demonstrated an improvement in
TIMI grade 3 flow comparing TNK with accelerated alteplase;
and a safety study has shown promising evidence that intra-
cranial hemorrhage is unlikely to be increased. In the TIMI 10B
trial, TNK-tPA (40 mg) and alteplase produced similar rates of
TIMI grade 3 flow at 90 min. Subsequently the ASSENT 1 trial
(Assessment of the Safety and Efficacy of a New Treatment)
demonstrated that the safety profile of TNK was comparable
to alteplase. To examine the impact of modest improvements
in perfusion, a large international trial was conducted
comparing TNK and accelerated alteplase with an expected
sample size of 16,949 patients in the ASSENT-2 trial.26
The 30-day mortality rates were almost identical for the
two groups e 6.18% for tenecteplase and 6.15% for alteplase.
Rates of intracranial hemorrhage were similar but fewer non-
cerebral bleeding complications and significantly less need for
blood transfusion (p ¼ 0.0002) were seen with tenecteplase.30
2.1.2.2. Candidates for use of thrombolytics. The eighth ACCP
guidelines on management of STEMI states that for patients
with ischemic symptoms characteristic of AMI of <12 h
duration and persistent STE, reperfusion (primary PCI or
fibrinolytic) therapy be implemented promptly after contact
with the health-care system (Grade 1A). In patients with AMI
who are candidates for fibrinolytic therapy, administration as
soon as possible (ideally within 30 min) after arrival at the
hospital or first contact with the healthcare system (Grade 1A)
is recommended. In healthcare settings where prehospital
administration of fibrinolytic therapy is feasible, it should be
administered (Grade 1A).13
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 5 6 6e5 8 5572In a country like India where there is a highly dispropor-
tionate ratio of patients presenting with ACS and catheter
laboratories (approximately 500) available; the recommenda-
tions should be highly pragmatic. Fibrinolytics thus prove a
very useful rescue option when intervention laboratories are
predicted not to be available immediately.
Fibrinolytic Therapy When There Is an Anticipated Delay
to Performing Primary PCI Within 120 Minutes of FMC:
Recommendations.32Classes of recommendations Definition Suggested wording to use
Class I Evidence and/or general agreement that a
given treatment or procedure is beneficial,
useful, effective.
Is beneficial, useful, effective.
Is recommended/is indicated
Class II Conflicting evidence and/or a divergence
of opinion about the usefulness/efficacy of
the given treatment or procedure.
Class IIa Weight of evidence/opinion is in favor of
usefulness/efficacy.
Should be considered
Class IIb Usefulness/efficacy is less well
established by evidence/opinion.
May be considered
Class III Evidence or general agreement that the
given treatment or procedure is not
useful/effective, and in some cases may
be harmful.
Is not recommended
Level of evidence A Data derived from multiple randomized
clinical trials or meta-analyses.
Level of evidence B Data derived from a single randomized
clinical trial or large non-randomized
studies.
Level of evidence C Consensus of opinion of the experts and/
or small studies, retrospective studies,
registries.Class I
In the absence of contraindications, fibrinolytic therapy
should be given to patients with STEMI and onset of ischemic
symptomswithin the previous 12 h when it is anticipated that
primary PCI cannot be performed within 120 min of FMC.
(Level of Evidence: A).
Class IIa
In the absence of contraindications and when PCI is not
available, fibrinolytic therapy is reasonable for patients with
STEMI if there is clinical and/or electrocardiographic evidence
of ongoing ischemia within 12e24 h of symptom onset and a
large area of myocardium at risk or hemodynamic instability.
(Level of Evidence: C).
Class III: harm
Fibrinolytic therapy should not be administered to patients
with ST depression except when a true posterior (inferobasal)
MI is suspected or when associated with ST elevation in lead a
VR. (Level of Evidence: B).
Fibrinolysis is recommended for patients with ischemic
symptoms characteristic of AMI: Timing of Fibrinolytic
Therapy.32 The benefits of fibrinolytic therapy in patients with ST
elevation or bundle-branch block MI are well established,
with a time-dependent reduction in both mortality and
morbidity rates during the initial 12 h after symptomonset.32
 Even when interhospital transport times are short, there
may be advantages to the immediate delivery of fibrinolytic
therapy versus any delay to primary PCI for patients with
STEMI and low bleeding risk who present within the first
1e2 h of symptom onset.32 Benefit from fibrinolytic therapy in patients who present
>12 h after symptom onset has not been established
although there remains consensus that consideration
should be given to administering a fibrinolytic agent in
symptomatic patients presenting >12 h after symptom
onset with STEMI and a large area of myocardium at risk or
hemodynamic instability if PCI is unavailable.32
2.1.2.3. Generations of thrombolytic drugs. Though fibrinolytic
therapy for AMI was first attempted in the 1950s, significant
advances have been made till date with the development of
newer agents that serves the purpose more efficiently. Since
discovery, the thrombolytic therapy has evolved over the
three generations of thrombolytic drugs.
1. First-generation agents33
First generation thrombolytic agents (SK and UK) are non-
fibrin specific agents which lack fibrin binding capabilities
and cause systemic plasminogen activation with concomi-
tant destruction of hemostatic proteins.34 While effective in
thrombolysis, their antigenic profile and propensity to cause
hemorrhagic complications led to the development of newer
thrombolytic drugs.35 A primary driving force behind the
development of the second generation tissue plasminogen
activator (tPA or alteplase) was its ability to bind to fibrin and
produce targeted thrombolysis.
(a) Streptokinase33
SK is a non-fibrin specific agent that activates both circu-
lating as well as clot-bound plasminogen and leads to sys-
temic lysis of fibrin. (The fibrin-specific agents predominantly
lyse clot-bound fibrin). It binds to plasminogen to form a
SKeplasminogen complex that converts freely circulating
plasminogen in the bloodstream to plasmin, which finally
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 5 6 6e5 8 5 573initiates fibrinolysis. The systemic plasminogen activation
with SK results in extensive fibrinogen depletion and
concomitant bleeding risks. In patients with AMI who are
treated with SK therapy, approximately 30% achieve TIMI
grade 3 flow by 90 min, and another 20% achieve TIMI grade 2
flow. The GUSTO-1 study showed a 30-day mortality rate of
7.3% and an intracranial hemorrhage rate of 0.54% with SK.
Besides the risk of bleeding, development of antibodies in
some patients (preventing its reuse), allergic reactions and
hypotension are some other disadvantages that results from
the nonspecific plasminogen binding of SK.
Col et al. treated 128 patients with SK and aspirin and ran-
domized the patients to either an IV bolus of heparin or no
heparin; the study reported no difference in coronary patency
at 24 h (86% versus 87%). The DUCCS-1 (Duke University Clin-
ical Cardiology Studies) investigators treated 250 patients with
anisoylated plasminogeneSK activator complex (APSAC) and
aspirin and randomized patients to heparin or no heparin.
Therewas a small difference in coronary artery patency (80% in
the heparin group versus 74% in the control group). In both
studies, moderate doses of heparin producedmarginal benefits
at the cost of increased bleeding.36
Trials like GISSI-2 with aspirin and several large studies
reported in 2005 with clopidogrel have established their use as
adjunctive antiplatelets with fibrinolytics. (Class I recom-
mendation, Level of Evidence: A).
The beneficial effects of aspirin and clopidogrel with fibri-
nolytic therapy are well established. These agents should be
given before or with the fibrinolytic. The recommendation that
clopidogrelbecontinued forupto1year isextrapolatedfromthe
experience with DAPT in patients with non-ST-elevation ACS.
The coadministration of other P2Y12 antagonists like pra-
sugrel and ticagrelor with fibrinolytic therapy has not been
prospectively studied, hence not recommended.32
In the GISSI-2 trial, a comparison of SK (SK, 1.5 MU IV infu-
sion over 30e60 min) and alteplase (tPA, 100 mg IV infusion
over 3 h) administered with heparin (12,500 U s.c. twice daily
until discharge from hospital, starting 12 h after beginning the
tPA or SK infusion) was carried out in patients with AMI
admitted to coronary care units within 6 h from onset of
symptoms. The incidence of major bleeds was significantly
higher in SK and heparin treated patients compared to alte-
plase (respectively, tPA 0.5%, SK 1.0%).37
(b) Urokinase
The fibrinolytic potential of human urine was first described
by Macfarlane and Pilling in 1947. The active molecule was
extracted, isolated, and named “urokinase” (UK) in 1952. Unlike
SK, UK directly activates plasminogen to form plasmin and
prior binding to plasminogen or plasmin is not necessary for
activity.33 The agent is nonantigenic, anduntoward reactions of
fever or hypotension are rare. In AMI patients receiving UK, the
patency rate at 60 min is around 60%.33 However, after the
manufacturer could not prove that because of the drug being
derived from the human source material, there is no risk of
transmitting infections, UK was not approved by the FDA and
production was suspended. Nevertheless, the drug is widely
used in Korea and the Asian-Pacific area, where the Throm-
bolysis in Myocardial Infarction in Korea (TIMIKO) trial
compared alteplase and UK in patients presented with AMI.33
The 30-day mortality rate was not significantly differentbetween the two treatment groups: 4.6% in the UK group and
4.4% in the alteplase group. Moreover, the incidence of ICHwas
0.3% in theUKgroup and 1.1% in the alteplase group. The risk of
major bleeding was 10% with UK and 9.7% with alteplase.33
2. Second-generation agents
(a) Alteplase
Alteplaseor recombinant tissueplasminogenactivator (rtPA)
is a second generation thrombolytic agent developed after mo-
lecular cloning techniques were used to express human tPA
DNA. Alteplase is a fibrin specific agent which converts plas-
minogen to plasmin in the presence of fibrin. It is a predomi-
nantly single-chain form of rtPA, which has been studied
extensively in the setting of coronary occlusion.33 Alteplase
helps to achieve TIMI grade 3 flow in 50e60% of patients at
90 min. In the GUSTO-I study of 41,000 patients with AMI, alte-
plase was found to be more effective than SK in achieving
vascular patency. Despite a slightly greater risk of intracranial
hemorrhage with rtPA, overall mortality was significantly
reduced. The patients who received alteplase had a 6.3% mor-
tality rate at 30 days and a 0.72% incidence of intracranial
hemorrhage. Compared with SK, alteplase resulted in a 1% ab-
solute reduction in death or nonfatal stroke.33 Clinically, re-
combinant t-PA (or alteplase) is capable of more rapid
thrombolysis and superior reperfusion compared with SK.
However, alteplase produces a significant amount of fibrinoge-
nolysis e although considerably less than either SK or UK and
there is no difference between alteplase and fibrin-nonselective
plasminogen activators in bleeding complications.38 Other lim-
itations of alteplase therapy include a delay in the time to
patency inmany patients and a substantial risk of re-occlusion.
There are also practical issues with the administration of alte-
plase: because of its extremely short half-life (3e6min) because
ofwhich it has to be administered as a continuous infusion over
aperiodof 30e60min. (*15mgbolusover1e2min, then0.75-mg/
kg infusion (50-mgmaximum) over 30min, followed by 0.5-mg/
kg infusion (35-mgmaximum)over60min; y15mgover1e2min,
then 50mg over 30min and 35mg over 60min. In addition, two
intravenous access sites are required, one for heparin and one
for alteplase. This complex infusion protocol makes alteplase
administration relatively cumbersome.38
(b) Anistreplase
Anistreplase is a second generation thrombolytic agent,
which results in a combined TIMI grade 2 and TIMI grade 3
flow rate of 50%e60% at 90 min. It has a side effect profile
similar to that of SK, but has the advantage of single-bolus
administration. The International Study of Infarct Survival
(ISIS)-3 showed a 10.5% mortality rate at 35 days with anis-
treplase and an ICH rate of 0.6%.
3. Third-generation agents
The third-generation fibrinolytic agents were developed
with an objective to improve safety, efficacy and ease of
administration of previous generations of thrombolytic
drugs.38 In an attempt to achieve better lytic characteristics
and less bleeding risk, genetic engineering techniques were
used to modify the wild-type t-PAmolecule, which consists of
several distinct domains which are known to be associated
with specific functional properties. (See Table below). Thus, it
was thought that genetic modification of the molecule to
delete specific domains could be a viable method of creating
an improved plasminogen activator. This improved
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permitting bolus administration, and would have a rapid
onset of action. It would be capable of achieving normal TIMI 3
flow in a large percentage of patients and would have a lower
potential for bleeding complications.38Structure: Second and third generation fibrinolytics.39
(a) Tenecteplase (TNK-t-PA; TNKase)
Tenecteplase isanovel thirdgenerationfibrinolyticdrugthat
results from the modification of native tPA at 3 sites. These
variationssubstantiallydecrease theclearanceofTNK-tPA from
plasma which results in longer half-life and higher fibrin spec-
ificity of the drug. Longer half-life of TNK-tPA allows the suc-
cessful administration of drug as a single bolus, the dose being
calculated on the basis of body-weight, in contrast to infusionCharacteristics of commonly used fibrinolytics in the treatment
approved for the management of STEMI.
Characteristic (units) Streptokinase
Generation I
Plasma half-life (min)a 18e23
Metabolisma Hepatic
Mechanism of actiona Activator complex
Fibrin specificitya Non-specific
Fibrin affinityc 
Antigenicc Yes
Allergic reaction (hypotension most common)c Yes
Method of administrationa 1 h Infusion
Weight-based dosingb No
Dosec 1.5 MU over
30e60 min
90-min Patency rates (w %)
d 50
TIMI Flow grade 3 (w %)
c 30
Rate of ICH (w %)
c 0.4
* Kunadian V & Gibson CM. Thrombolytics and Myocardial Infarction. Ca
Adapted and modified from;
a Menon V, Harrington RA, Hochman JS, Cannon CP, Goodman SD, Wil
therapy in acutemyocardial infarction: the Seventh ACCP Conference on A
b Hilleman DE, Tsikouris JP, Seals AA, et al. Fibrinolytic agents for the m
cotherapy 2007;27(11):1558e1570.
c Boden WE, Eagle K, Granger CB. Reperfusion strategies in acute ST-se
contemporary management options. JACC 2007;50(10):917-929.
d Pollack CV, Antman EM, Hollander, JE. Management of Patients With
gency Department Practice. Ann Emerg Med. 2008;52:344-355required for alteplase. In addition, TNK-tPA manifests greater
fibrin specificity than alteplase, resulting in less fibrinogen
depletion. In studies of acute coronary occlusion, TNK-tPA per-
formedat leastaswell asalteplase, concurrentwithgreater ease
of administration. Theefficacyanddosing of tenecteplase in thetreatment of acuteMIwere evaluated in the TIMI 10A, TIMI 10B,
ASSENT-1, andASSENT-2 trials. Tenecteplasedemonstrated90-
min TIMI grade 3 flow rates of 59%e64%. The primary endpoint
of 30-day all-cause mortality occurred in 6.18% of the ten-
ecteplasegroupand6.15%of thealteplasegroup.The incidences
of ICH were similar to alteplase inmajority of the trials.
(b) Reteplase (r-PA)
It is a 1st third generation recombinant form of t-PA that
operates in the presence of fibrin (i.e. it is fibrin specific).33of STEMIa- d. There are several fibrinolytic agents currently
Altepase Tenecteplase Reteplase
II III III
3e8 18e20 15e18
Hepatic Hepatic Renal
Direct Direct Direct
þþ (high) þþþ (very high) þ (moderate)
þþ þþþ þ
No No No
No No No
Bolus þ90 min
infusion
Single Bolus Double bolus
Yes Yes No
Up to 100 mg
in 90 min
30e50 mg based
on weight
10 U  2 (30 min apart),
each over 2 min
75 75 80
50 w60 w60
0.4e0.7 0.9 0.8
rdiovas Ther. 2012;30:e81ee88.
cox RG, Schu¨nemann HJ, Ohman EM. Thrombolysis and adjunctive
ntithrombotic and Thrombolytic Therapy.Chest 2004;126;549Se575S.
anagement of ST-segment elevation myocardial infarction. Pharma-
gment elevation myocardial infarction: a comprehensive review of
ST-Segment Elevation Myocardial Infarction: Implications for Emer-
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neered by means of recombinant DNA technology, derived
from tissue plasminogen activator (t-PA). Reteplase mimics
the endogenous tissue plasminogen activator (t-PA), a serine
protease, converting plasminogen to plasmin and thereby
precipitating thrombolysis. Modifications in molecular struc-
ture of Reteplase results in some of the unique properties of
drug including high fibrin specificity, low fibrin affinity
(binding), longer half-life and greater thrombolytic potency in
comparison to t-PA. A double bolus reteplase (10 þ 10 MU)
utilized in the RAPID trial resulted in complete, rapid and
sustained thrombolysis of IRA at 90min and 5e14 day (63% vs.
49%, p ¼ 0.019; and 88% vs. 71%, p < 0.001) compared with
alteplase and improved regional and global left ventricular
function at discharge.11
2.1.2.4. Rationale for the utilization of bolus thrombolytic agent
with a relevance to conditions in India. Evidence from many
clinical trials now indicates that two characteristics of a
thrombolytic drug determine its efficacy: (1) the ability to
achieve early and complete reperfusion (2) the ease of
administration to ensure the earliest initiation of treatment.16
Despite the lack of clinical benefit over conventional agents,
bolus agents have number of potential treatment advantages
that favor their clinical utilization.12 These benefits are sum-
marized below.
(1) Ease of treatment
 Utilization of bolus fibrinolytics treatment could aid in
more rapid treatment of AMI, since there is unequivocal
evidence that earlier delivery of therapy is associated
with greater myocardial salvage and improved prognosis
to improve survival.40
 Reducing the time to treatment, particularly the “door-to-
drug” time, has been identified as a critical target. An
increased door-to-drug time has been shown to relate
directly to increased mortality. The time from “the deci-
sion” to “the start of drug” can be reduced if a simple,
bolus fibrinolytic agent is available.12
 The advantage of single-bolus therapy in relationship to
compliance was established in ISIS-3, in which 95% of
patients assigned to anistreplase actually received the
drug compared with only 89% and 90% of patients in the
alteplase and SK groups, respectively.12
 Further, patients administered double-bolus reteplase
therapy received the drug 15 min sooner than did those
treatedwith alteplase infusion in a study by Hilleman and
colleagues.12
(2) Prehospital treatment
 Time from symptom onset to initial treatment with
fibrinolysis has not improved over the last 2 decades.12
 Although some success has been achieved in abbrevi-
ating the door-to-needle time as it relates to the admin-
istration of fibrinolytic therapy, the same cannot be said
for the delay that persists between symptom onset and
hospital arrival. Indeed, despite an understanding of the
demographic, cultural, and other barriers that exist and
an effort through intense public education programs to
abbreviate the time from symptom onset to presentationfor appropriate therapy among patients with chest pain
syndromes, no improvement in time to arrival to hospital
has been achieved.40
 Hence, among regions and countries (true for India)
where these delays are an important factor, and espe-
cially where emergency medical services transport times
exceed 1 h, there is now substantial motivation to move
toward pre-hospital bolus fibrinolysis in the ambulance
or home. Bolus fibrinolytic therapy may be even more
advantageous in this setting, where simplicity and lack of
need for multiple intravenous lines is at a premium.40
 In an overview of six randomized trials involving 6434
patients, the utilization of a pre-hospital thrombolysis
resulted in significantly earlier treatment of patients,
compared to a conventional in-hospital strategy (104 min
vs 162 min; p ¼ 0.007). A significant improvement in in-
hospital mortality was also evidenced by this approach.
In the Comparison of Angioplasty and Prehospital
Thrombolysis in Acute Myocardial Infarction (CAPTIM)
trial, a prehospital thrombolysis strategy compared
favorably to primary angioplasty. Utilization of bolus fi-
brinolytics therapy enhances the feasibility of this
promising strategy.12
 In the Early Reteplase-Thrombolysis in Myocardial
Infarction (ER-TIMI) 19 study, utilization of prehospital
reteplase decreased the time to initial treatment by
32 min compared to conventional in-hospital adminis-
tration. As a result 49% of patients received initial therapy
within 30 min of health-care contact (compared to only
5% in the classically treated group; p < 0.0001).12
(3) Decrease in medication errors
 The “therapeutic window” for thrombolytic therapy is
small, and the potential for adverse outcome from dosing
errors is high.41 Incorrect dosing of fibrinolytic therapy
has been reported to occur 5%e12% of the time. Several
studies have reported higher mortality, stroke, and major
hemorrhagic event rates in patients who received incor-
rect doses of fibrinolytic agents.42
 The ease of administration with bolus fibrinolytic agents
can reduce medication errors. These errors have been
associated with adverse outcomes and longer hospital
stays in this population. A surprisingly high percentage of
medication errors (that is, an incorrect dose or infusion
duration) have been documented with traditional bolus
followed by infusion alteplase therapy.12 In GUSTO-I, 12%
of the 41,021 patients treated with alteplase or SK infu-
sion had a medication error. 13.5% of patients treated
with streptokinase and 11.5% of patients treated with
t-PA were subjected to a medication error (e.g., incorrect
dose or infusion length).12
 Most importantly, 30-day mortality was significantly
higher in patients withmedication errors: For t-PA dosing
errors, mortality was 7.7% versus 5.5% for patients who
received the correct t-PA dose (p < 0.001); findings were
similar for streptokinase.41
 In a Registry of Myocardial Infarction, >71,000 patients
who received a dose of alteplase>1.5mg/kg had a 2.3-fold
increase in ICH, suggesting that medication errors with
bolus and infusion fibrinolytic therapymay be important.
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Myocardium Early (InTIME)-II trial, there were more
dosing errors in the alteplase group than in the single
bolus third generation group 7.3% vs. 5.7%, p < 0.001).12
 Mortality was higher among alteplase treated patients
with medication errors vs. those receiving the correct
Alteplase dose (12.5% vs. 5.9%, p < 0.001).
 ICH also was significantly increased among alteplase-
treated patients with medication errors (1.4% vs. 0.6%
with the correct alteplase dose).12 In the ASSENT-3 PLUS
(Assessment of the Safety and Efficacy of a New Throm-
bolytic Regimen-3 Plus) study, approximately 20% of pa-
tients received >105% of the correct dosage of weight-
based single-bolus tenecteplase administered pre-
hospital; this was associated with an approximately 2-
fold rate of intra-cerebral hemorrhage versus lower
doses among patients receiving unfractionated heparin
as the concomitant antithrombin agent.
 More recent data studies showed that use of a bolus
thrombolytic agent reduced the rate of medication errors.
Thus, use of the simpler bolus thrombolytic agents may
improve overall clinical outcome by ensuring accurate
dosage.41 For the double-bolus agent reteplase, the rate of
medication errors also has been low; only 1% of patients
did not receive the full reteplase dose in one study,
compared with 4% for alteplase (p < 0.03).12
 Within contemporary emergency departments, physi-
cians and nurses are required to deal with a growing and
increasingly complicated array of available therapies for
acute coronary syndromes. These demands are often
accented by resource constraints; hence, simple bolus
fibrinolytic regimens are a welcome innovation, and such
regimens are less likely to engender medication errors.40
2.1.3. Thrombolyse now and stent later (pharmacoinvasive
approach)
Acute ST-Elevated Myocardial Infarction (STEMI) is a medical
condition caused by the coronary plaque rupture/erosion and
resultant thrombosis leading to an occluded epicardial
infarct-related artery (IRA).12 Myocardial reperfusion therapy
(Fibrinolysis/PCI) is based on the concept that after a coronary
vessel is occluded, myocardial cell death starts from the
endocardium (inner layer) outward to the epicardium (outer
layer). When the occlusion is released and myocardial blood
flow is restored, the size of the final MI is determined by the
amount of myocardium supplied by the infarct-related artery
(IRA), the time from occlusion to reperfusion and the extent of
collateral blood supply.43
Prehospital thrombolysis appears safe and effective and is
associated with a substantial gain in time to treatment. A
meta-analysis of studies comparing prehospital and inhos-
pital thrombolysis has shown a relative reduction in short-
term mortality of 17% with prehospital thrombolysis. There-
fore, the Comparison of Angioplasty and Prehospital Throm-
bolysis in acute Myocardial infarction (CAPTIM) trial was set
up to compare prehospital thrombolysis and primary PCI in
more than 800 patients with STEMI. Patients randomized <2 h
after symptom onset had a strong trend toward lower 30-day
mortality with prehospital thrombolysis compared with those
randomized to primary PCI (2.2% versus 5.7%, p ¼ 0.058).44All-cause mortality at 5 years in CAPTIM trial was 9.7% in
the prehospital fibrinolysis group when compared with 12.6%
in the primary angioplasty group. For patients includedwithin
2 h, 5 year mortality was 5.8% in the prehospital fibrinolysis
group when compared with 11.1% in the primary angioplasty
group.45
The 5-year follow-up was consistent with the 30-day out-
comes of the trial, showing similar mortality for primary PCI
and a policy of prehospital lysis followed by transfer to an
interventional center.45
The CAPTIM trial confirms that the benefit of intravenous
thrombolysis is extremely time sensitive and when treatment
is established in the first 2 h after symptom onset, the so-
called “golden hour,” survival dramatically increases.44
The PRAGUE trial showed that although angioplasty was
performed within 1 h after the beginning of the SK infusion
and openedmore than twice asmany vessels thanwith the SK
infusion, this did not result in better patient outcome. More
bleeding complications were observed when SK was com-
bined with heparin given in the cath lab, hence could be one
among many factors to offset the mortality benefit with SK
compared to the policy of thrombolysis followed by transfer to
PCI centre or direct transfer to the PCI centre.46
Based on the evidence so far, the 2013 ACC/AHA focused
update for the management of patients with acute STEMI
states that patients presenting to the non-PCI centers, receive
fibrinolytic therapy as a primary reperfusion therapy and to
should be transferred as soon as possible to a PCI-capable
facility where PCI can be performed either when needed or
as a pharmacoinvasive strategy.11 Early catheterization after
thrombolysis is to be preferred to conservative management.
At 12 months, patients in the invasive group had a lower rate
of death, reinfarction, or revascularization, and trended to-
ward reduced death or reinfarction. Thus, results from the
GRACIA study support a strategy of “lyse now, stent later”.47
Intravenous thrombolysis although one of the accepted
modes of treatment for ST-elevation myocardial infarction,
carries a higher risk of reinfarction than primary PCI. There
are few data comparing PPCI with thrombolysis followed by
routine angiography and PCI. The pharmacoinvasive strategy
(thrombolysis followed by routine angiography) with PPCI was
analyzed from a nationwide registry which included 223
centers and 1714 patients over a 1-month period at the end of
2005, with 1-year follow-up. Sixty percent of the patients un-
derwent reperfusion therapy, 33% with PPCI and 29% with
intravenous thrombolysis (18% prehospital). At baseline, the
Global Registry of Acute Coronary Events score was similar in
thrombolysis and PPCI patients. Time to initiation of reper-
fusion therapy was significantly shorter in thrombolysis than
in PPCI (median 130 versus 300 min). After thrombolysis, 96%
of patients had coronary angiography, and 84% had subse-
quent PCI (58% within 24 h).48 In-hospital mortality was 4.3%
for thrombolysis and 5.0% for PPCI. In patients with throm-
bolysis, 30-daymortality was 9.2%when PCI was not used and
3.9% when PCI was subsequently performed. One-year sur-
vival was 94% for thrombolysis and 92% for PPCI (p ¼ 0.31).
Thus when used early after the onset of symptoms, a phar-
macoinvasive strategy that combines thrombolysis with a
liberal use of PCI yields early and 1-year survival rates that are
comparable to those of PPCI (Fig. 1).48
Fig. 1 e One-year survival according to use and type of
reperfusion therapy. Adapted from e Circulation
2008;118:268e276.
Delay Target
Preferred for FMC to ECG
and diagnosis
10 min
Preferred for FMC to fibrinolysis
(‘FMC to needle’)
30 min
Preferred for FMC to primary
PCI (‘door to balloon’) in
primary PCI hospitals
60 min
Preferred for FMC to
primary PCI
90 min
(60 min if early presenter
with large area at risk)
Acceptable for primary
PCI rather than fibrinolysis
120 min
(90 min if early presenter
with large area at risk)
if this target cannot be
met, consider fibrinolysis.
Preferred for successful
fibrinolysis to angiography
3e24 h
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combines the benefits of mechanical and pharmacologic
reperfusion.19 Thus to ensure maximum benefit of the phar-
macoinvasive approach which best suits a vast country like
India, where infrastructure is not developingwith the speed of
population, the use of more efficient thrombolytic agents
which can be administered without weight based calculation
(viz. reteplase) should be the treatment of choice. First medi-
cal contact (small nursing homes, satellite hospitals, casualty
of bigger hospitals) should be “pre hospital” areas of throm-
bolysis which will not only reduce the health costs but more
importantly results in loss of myocardium. Early thrombolysis
and early angiography to all should be the future of managing
STEMI in Indian context.8 More importantly, physician-based
smaller hospitals (in villages, smaller towns or suburbs of
cities) can play a crucial role, by administering thrombolytic
agent to these patients at the time of firstmedical contact with
agents like third generation thrombolytics, which are char-
acterized by the ease of administration and lack of anaphy-
lactic reactions. The patient thus gets enough time to move to
a catheter lab facility in next 3e24 h. This time also allows
them to arrange for finances, gathermanpower, and complete
insurance formalities (all very important in Indian context). In
addition, this breathing period has not done the myocardium
any harm, due to early thrombolysis and recanalised culprit
artery. Since this population comprises of very young STEMI
patients where the predominant pathology in the coronary
artery is a thrombus rather than the traditional atheroscle-
rotic plaques; such patients if treated early with effective
thrombolysis, can have practically normal coronaries. In
future for this special Indian subset, every attempt should be
made for early thrombolysis because that could be the only
therapy required for these young individuals and unnecessary
stenting would get avoided.8 Public awareness should be
increased about early detection (symptoms) of AMI, impor-
tance of confirmed diagnosis of AMI, early treatment and the
concept of golden hour.The earlier ACC/AHA and ESC STEMI guidelines recom-
mended PCI as the initial approach to management of STEMI,
contingent upon treatment at centers with a skilled PCI lab-
oratory and rapid initiation. Appropriately selected patients
undergoing primary PCI were shown to have lower rates of
nonfatal re-infarction, stroke, and short-term mortality than
thrombolytic recipients in a meta-analysis of data from 23
randomized trials enrolling thrombolytic-eligible patients
with STEMI. However, for many patients these criteria for
primary PCI to be preferred will not be met and it was
important to note that the guidelines also state that there is no
strong preference between PCI and thrombolysis as the choice
of initial reperfusion therapy in patients who present within
3 h after symptom onset.49
Several randomized trials and three contemporary meta-
analyses have shown that early routine post-thrombolysis
angiography with subsequent PCI (if required) reduced the
rates of reinfarction and recurrent ischemia compared with a
‘watchful waiting’ strategy, in which angiography and
revascularization were indicated only in patients with spon-
taneous or induced severe ischemia or LV dysfunction. The
benefits of early routine PCI after thrombolysis were seen in
the absence of increased risk of adverse events (stroke or
major bleeding).
Thus, early referral for angiography with subsequent PCI
(if indicated) should be the standard of care after throm-
bolysis: the so-called ‘pharmacoinvasive’ strategy. A crucial
issue is the optimal delay between lysis and PCI: there was a
wide variation in delay in trials, from a median of 1.3 h in
the Combined Angioplasty and Pharmacological Interven-
tion versus Thrombolytics ALone in Acute Myocardial
Infarction (CAPITAL-AMI) trial to 16.7 h in the GRACIA-1
trial. Based on the three most recent trials, all of which
had a median delay between start of lysis and angiography
of 2e3 h, a time window of 3e24 h after successful lysis is
recommended.50
The ESC 2012 guidelines have summarized important
delays and treatment goals in the management of acute
STEMI.50
Region of molecule Function
Fibronectin finger High fibrin binding
Epidermal growth factor Receptor binding (liver)
Kringle 1 Receptor binding
Kringle 2 Low fibrin binding (stimulation)
Protease domain Plasminogen-specific,
PAI-1binding site
Carbohydrates Mediators of plasma clearance
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mately the first 6months, 84 patients received care within this
quality improvement programme. The mean time of arrival
from symptom onset was 170 min, with 77% of patients
arriving by ambulance with a mean transport time of 44 min
(5e99 min). The mean time from hospital arrival to PCI was
69 min for patients undergoing primary PCI while the mean
time to PCI after fibrinolytic therapy with the pharmacoinva-
sive strategy was 480 min.6
2.1.4. Comparison of various thrombolytic agents
2.1.4.1. Bolus vs. prolonged infusion. The GUSTO angiographic
substudy demonstrated that delayed (>90 min) restoration of
TIMI 3 flow was not associated with an improved outcome
compared with restoration of TIMI 3 flow at 90 min. Hence for
optimal treatment of AMI, normal blood flow (TIMI 3) in the
infarct-related artery should be reestablished as rapidly as
possible and maintained.51
Intravenous standard-dose alteplase was superior to intra-
venous SK in achieving early reperfusion, as confirmed by the
GUSTO angiographic substudy using accelerated alteplase
administration. The 90-min TIMI 3 flow rate in the GUSTO
angiographic substudy was 54% with accelerated alteplase
administration,whichwas slightly higher than the 90-minTIMI
3 flow rate with standard dose alteplase (49.0%).51
Tenecteplasealsooffersasimple,efficient,5-sadministration
over a single bolus. TIMI 10B compared 40-mg doses of ten-
ecteplase and an accelerated alteplase regimen. The rate of TIMI
grade 3 flow at 90 min, was 62.7% in the accelerated alteplase
group and 62.8% in the tenecteplase 40-mg group.33
RAPID 1 evaluated three bolus regimens of reteplase in com-
parisonwith a 3h infusion of alteplase. RAPID 2 compared the 10
MU þ 10 MU double bolus regimen of reteplase with the accel-
erated regimen (90min infusion)ofalteplase.Theresultsof these
studiesshowedthatreteplaseopenedmorearteriesmorequickly
than did alteplase. Angiography at both 60 and 90min evinced a
higherrateofpatencyandgreaterTIMI3flowrateswithreteplase
thanwith alteplase. In RAPID 1, at 90min, TIMI 3 flow rateswere
63% for reteplase compared to 49% for alteplase (p < 0.05). Thus
the reteplase resulted in a higher TIMI 3 patency rate compared
with standard-dose alteplase (87.8% vs. 70.7%, p< 0.01). In RAPID
2, TIMI 3 flowwas 60% vs. 45%, respectively, (p< 0.05).52
Very early administration of thrombolytics, within
70e90 min of onset of chest pain, is associated with improved
survival and left ventricular function. Completeness of
thrombolysis is also critical for achieving optimal outcomes.51
A practical advantage of reteplase 10 þ 10 U regimen is the
ease of bolus administration compared with the relative
complexityof infusionsof varyingdosesofalteplase.TIMI3flow
appears to occur earlier after bolus administration of reteplase
thanwithstandard-dosealteplase,whichwasnot thecasewith.
Tenecteplase in TIMI 10B trial. Reteplase thus achieves
more rapid, complete, and sustained thrombolysis of the
infarct related artery than standard-dose alteplase. The early
and improved infarct-related artery patency was associated
with improved global and regional function at hospital
discharge in reteplase treated patients.51
2.1.4.2. Non-weighted bolus vs weighted bolus. AMI is an
emergency and every minute is crucial. Dramatic reductionsin mortality can be achieved if treatment is obtained during
the first golden hour.53 The dosing of intravenous regimens is
based on body weight. Reteplase is a simpler alternative since
it is administered as a bolus and dosing is not based onweight.
Therefore with reteplase fibrinolytic administration is
simplified, which may be especially important in the pre-
hospital setting.19
The use of bolus fibrinolytic therapy, such as reteplase or
tenecteplase, is appealing to emergency personnel and may
enable treatment to be initiated more quickly than with an
agent administered by infusion.19
Non-weight based dosing may have the potential to
decrease treatment errors, because visual approximation of a
patient’s weight is subject to substantial dosage errors.19
In the ASSENT-3 PLUS study, approximately 20% of patients
received >105% of the correct dosage of weight-based single-
bolus tenecteplase administered prehospital; this was associ-
ated with an approximately 2-fold rate of intra-cerebral hemor-
rhage versus lower doses among patients receiving
unfractionated heparin as the concomitant antithrombin agent.
Mortality was also shown to be increased in patients
receiving an incorrect dosage of SK or alteplase, which are
dosed by intravenous infusion based on body weight.19 Rete-
plase which is a fixed dose double-bolus injection can be
administered irrespective of age or weight, which can be safe
and conveniently done by paramedics in prehospital or
ambulance setting.19
2.1.4.3. Molecular structural and functional differences among
thrombolytic agents. Alteplase, was the first fibrin specific
agent classified as a second generation fibrinolytic to be syn-
thesized through genetic modification of wild-type tissue
plasminogen activator by using recombinant DNA technology.
Both the wild-type tPA and alteplase consist of several do-
mains, each of which is associated with a specific function.
Protease domain is responsible for the conversion of plas-
minogen to plasmin. The protease domain contains a binding
site for plasminogen activator inhibitor type 1 (PAI-1), and the
molecule contains carbohydrate side chains that serve as
mediators of plasma clearance.
Kringle 2 domain, associated with low-affinity fibrin bind-
ing, accelerates conversion of fibrinogen to fibrin.
Fibronectin finger-like domain, which is associated with
high affinity fibrin binding; an epidermal growth factor
domain that accelerates clearance in the liver Kringle 1
domain associated with receptor binding.54
Function of different domains are explained in the
following table.
Function of different domains in wild-type t-PA.38
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tPA. The molecular structure of Reteplase differs from wild-
type t-PA in the lack of three domains (finger, epidermal
growth factor (EGF) and kringle-1) and because it is produced
in Escherichia coli cells, reteplase also lacks carbohydrate side
chains (unglycosylated). These differences in molecular
structure between reteplase and alteplase account for their
different pharmacological profiles.16 A major difference be-
tween reteplase and alteplase, is the deletion of kringle-1 and
epidermal growth factor domains in reteplase.
These domains facilitate binding to receptors in the liver
and enhance hepatic clearance of alteplase. Therefore dele-
tion of the kringle-1 and EGF domains contributes to the
longer half-life of reteplase (13e16 min vs 3e6 min with alte-
plase). This longer half-life of reteplase allowsmaintenance of
therapeutic plasma concentrations and permits an intrave-
nous bolus-dosing regimen.16
Unlike reteplase, which is a deletion mutant of wild-type
tPA, tenecteplase is derived from wild-type tPA by intro-
ducing a point mutation in the carbohydrate side chain that
reduces the clearance of the molecule and results in its longer
half-life.38
 Fibrin Affinity and Hemostatic plugs:
The finger domain, a fibronectin-like projection promotes
high-affinity fibrin binding in alteplase. In reteplase this
domain is deleted hence at therapeutic concentrations, the
fibrin-binding affinity of reteplase is approximately 30% that
of alteplase. Although fibrin specificity is desirable to mini-
mize the occurrence of plasminemia which occurs with SK,
very high-affinity fibrin binding may cause high concentra-
tions of t-PA to accumulate at surface receptors on the fibrin
clot. As a result, fibrinolysis may occur more slowly, since the
fibrinolytic activity must progress from the surface to the
interior of the clot.
Reteplase lacks the fibronectin like F (finger) domain,
which accounts for the high binding of t-PA to fibrin. Yet, the
kringle 2 domain common to reteplase and t-PA also con-
tributes to fibrin interaction (although not with such high af-
finity as the finger domain). Therefore, reteplase does not bind
as highly to fibrin compared to native t-PA.38 Due to lower
fibrin binding affinity, Reteplase binds loosely to fibrin and has
the ability to penetrate into thrombi which allow for more
efficient clot penetration and lysis.
The concentration-dependent lysis of plasma clots by
reteplase and alteplase, after 4 h of incubation, has shown
that reteplase has the same maximal lytic efficacy as Alte-
plase at equipotent concentrations. However, reteplase has
less lytic efficacy in platelet-rich plasma clots and aged clots,
suggesting that reteplase preserves hemostatic plugs andmay
thus produce fewer bleeding complications than does
alteplase.16
In humans, following intravenous bolus doses of reteplase,
plasma fibrinogen concentrations remain unchanged except
at higher doses; however, a-antiplasmin and fibrin-D dimer
levels exhibited dose-related decreases. In patients with AMI,
reteplase results in significantly decreased levels of fibrin-
ogen, plasminogen, a-antiplasmin, fibrinogen degradation
products, and fibrin D-dimers.Compared with other molecules used in clinical practice,
TNKase has the highest degree of fibrin specificity and bind-
ing.55 However, the increased fibrin specificity may not
necessarily produce a dramatic increase in the rate of clinical
reopening of occluded arteries, as tenecteplase was not
significantly better than alteplase in terms of maximal speed
of clot lysing.56
 Antigenicity
Alteplase have not demonstrated presence of any antige-
nicity.57 Like Alteplase (tPA), the varients of wild-type tPA,
reteplase has been shown to have low antigenic activity; an-
tibodies to reteplase have not been observed in any of 2400
patients tested for antibody formation. This property has a
clinically significant advantage over the first generation agent
streptokinase and its derivatives.16 Tenecteplase too has a
antigenic profile similar to that of t-PA.39
2.1.4.4. Ease of administration is important especially in
emergency settings. The complicated regimens of the second-
generation drugs may partly account for their underuse. For
instance, Alteplase, has to be given as an accelerated intrave-
nous infusion regimen involving a bolus followed by two timed
infusions whereas, Reteplase can be administered a double
bolus and dosing does not depend on the patient’s weight16
whereas for tenecteplase though it can be given as a single
bolus, the dose needs to be calculated based on the patient’s
body-weight which is cumbersome in an emergency setting.
With Tenecteplase, the entire dose can be delivered over a
single 5-s bolusdno infusion or second bolus is necessary.58
Reteplase treatment reduced the median door-to-needle
time by 32 min in the ER-TIMI (Early Retavase-Thrombolysis
In Myocardial Infarction) 19 study, which also led to earlier
ST-segment resolution.59 Adherence to the ACC-AHA guide-
lines, as well as knowledge about the available fibrinolytic
agents, is essential for physicians and pharmacists to make
informed decisions regarding appropriate pharmacologic
reperfusion strategies.54
2.1.4.5. Reinfarction rates. Reinfarction is the visible sign of
coronary reocclusion. This is supported by the association of
angiographically proved IRA reocclusion with symptomatic
reinfarction.60 A moderate hypercoagulative state, character-
ized by increased thrombin and plasmin activation, is known
in patients with AMI. The administration of thrombolytic
agents in these patients causes an additional pro-coagulant
effect besides the desired activation of the plasminogen-
plasmin system.61
Both tenecteplase and teteplase thrombolytic regimens
have a pro-coagulant action in addition to the preexisting
hyper-coagulative state of patients with AMI. This effect is
associated with a significant increase in kallikrein activity.
The amount of the pro-coagulant effect, however, is only
moderate comparedwith other non-clot-specific thrombolytic
agents like streptokinase.61 Tenecteplase and reteplase, hav-
ing plasma half-lives of less than 25 min, require effective
immediate adjunctive antithrombotic support at a time of
intense thrombotic and inflammatory activity at the site of the
plaque.60
Agent Dosing and administration
Streptokinase 1,500,000 IU i.v. infusion over 30e60-min
Reteplase Two 10-U boluses, each administered over
2 min, 30 min apart
Alteplase 90-min infusion: 15-mg i.v. bolus, followed
by 0.75 mg/kg (maximum dose 50 mg)
infused over 30 min, followed by 0.50 mg/
kg (maximum dose 35 mg) infused over
60 min
3-h infusion: total dose of 100 mg, with
60 mg administered within the first
hour, and 20 mg administered during
second and third hour
Tenecteplase Single bolus administered over 5 s; dose
based on patient weight (maximum dose
50 mg): <60 kg: 30 mg; 60e69 kg: 35 mg; 70
e79 kg: 40 mg; 80e89 kg: 45 mg; and
90 kg: 50 mg
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and antiplatelet (aspirin) therapy was evaluated in the GISSI-2
and ISIS-3 trials with strong indications from angiographic
studies that intravenous heparin considerably contributes to
sustained IRA patency.62
If the delay between fibrinolysis and PCI is too long, pa-
tients are exposed to the risk of reinfarction and recurrent
ischemia while they await PCI, and patients in whom reper-
fusion after fibrinolysis is not successful may not be able to
undergo rescue PCI quickly enough to salvage myocardium.
Therefore, catheterization and PCI should be performed a few
hours after fibrinolysis (within 6 h).63
The re-infarction rates were significantly greater for ten-
ecteplase (9.3%) than reteplase (4.2%).60 High rates of re-
infarction reflect variation in the precise method of adminis-
tration of the fibrinolytic agents and associated antith-
rombotic treatment within the prehospital environment.
Maintenance of heparin levels by heparin infusion is critical at
a time of intense thrombotic and inflammatory activity (AMI).
The effect of the lack of a heparin infusion was reduced for
reteplase by the administration of its second dose within the
recommended limit of 30min. For tenecteplase a treatment to
hospital arrival time of under 30 min was associated with a
very high, re-infarction rate of 9.3%, indicating that even
within this interval a heparin infusion is vital. Though in the
ASSENT-3 PLUS trial, unfractionated heparin was adminis-
tered in the ambulance where the reinfarction rate was 5.8%
after prehospital tenecteplase, the difference in the reinfarc-
tion rates was non-significant (4.0% vs 5.9%), compared to
those for whom it was started in hospital.60
2.1.4.6. Bleeding risks of thrombolytics. As the first generation
thrombolytic agents are not fibrin specific, they convert
circulating plasminogen to plasmin. As there is a constant
equilibrium between circulating plasminogen and plasmin-
ogen in thrombus, there is depletion of circulating plasmin-
ogen reducing clot lysis and efficacy of the thrombolytic
agents. This is known as Plasminogen steal. Moderately fibrin
specific agents like reteplase overcome this limitation and are
also more effective than first generation agents, namely
SK.19,64
Higher binding affinity for fibrin also decreases the amount
of circulating unbound Alteplase and decreases its interaction
with the thrombus. In contrast, Reteplase has a lower fibrin
binding affinity for fibrin in vitro, which may increase the
amount of unbound drug available to act elsewhere on the clot
and improve penetration into the clot.65
Very high fibrin-affinity may cause high concentrations of
t-PA to accumulate at surface receptors on the fibrin clot. As a
result, fibrinolysis may occur more slowly, since the fibrino-
lytic activity may progress from the surface to the interior of
the clot. Due to lower fibrin binding affinity compared to
alteplase (þþþ) and tenecteplase (þþþþ).
Reteplase (þ) binds loosely and irreversibly to the fibrin by
virtue of which it gets an ability to penetrate into thrombi and
allows for more efficient clot penetration and lysis. The
concentration-dependent lysis of plasma clots by reteplase
and alteplase, after 4 h of incubation, has shown that rete-
plase has the same maximal lytic efficacy as alteplase at
equipotent concentrations. However, reteplase has less lyticefficacy in platelet-rich plasma clots and aged clots, suggest-
ing that it preserves hemostatic plugs and may thus produce
fewer bleeding complications than those with higher fibrin
affinity.163. Pearls for clinical use12,13,66
3.1. Dosage and method of administration of various
thrombolyticsConcomitant use of antithrombin therapy
Is anticoagulant therapy required with thrombolytics?
Parenteral anticoagulation has been used extensively
during and after fibrinolysis and should preferably be given
until revascularization (if performed). Otherwise it should be
given for at least 48 h or for the duration of hospital stay, up to
8 days. UFH was found to improve coronary patency after
alteplase but not after streptokinase. Careful dosing and close
monitoring of intravenous UFH therapy is mandatory; aPTT
values >70 s are associated with a higher likelihood of
bleeding, reinfarction and death.50
In spite of an increased risk of major bleeding, the net
clinical benefit favored enoxaparin over UFH in more recent
studies namely in the ASSENT 3 trial (n ¼ 6095), where a
standard dose of enoxaparin given in association with ten-
ecteplase for a maximum of 7 days reduced the risk of in-
hospital reinfarction or in-hospital refractory ischemia when
compared with UFH.50
In the large ExTRACTeTIMI 25 trial, a lower dose of enox-
aparin associated with a reduction in the risk of death and
reinfarction at 30 days when compared with a weight-
adjusted UFH dose.
Tenecteplase, aspirin, enoxaparin and clopidogrel
comprise the antithrombotic combination that has beenmost
extensively studied as part of a pharmacoinvasive strategy,
viz. Trial of Routine.
ANgioplasty and Stenting after Fibrinolysis to Enhance
Reperfusion in acute myocardial infarction (TRANSFER),
NORwegian study on DIstrict treatment of ST-Elevation
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GRACIA-3.50
 For patients with acute STEMI, in addition to aspirin and
other antiplatelet therapies, we recommend the use of
antithrombin therapy over no antithrombin therapy (Grade
1A), including for those patients receiving fibrinolysis (and
regardless of which lytic agent is administered), primary
PCI, or patients not receiving reperfusion therapy.13
 UFH13
B For patients receiving streptokinase, we suggest admin-
istration of either IV UFH. (5000-U bolus followed by
1000 U/h for patients >80 kg, 800 U/h for <80 kg) with a
target activated partial thromboplastin time (APTT) of
50e75 s or subcutaneous UFH (12,500 U q12h) over no UFH
therapy for 48 h (both Grade 1B).
B For patients receiving alteplase, tenecteplase, or reteplase
for fibrinolysis in AMI, we recommend administration of
weight-adjusted heparin (60 U/kg bolus for amaximumof
4000 U, followed by 12 U/kg/h [1000 U/h maximum])
adjusted to maintain an APTT of 50e70 s for 48 h
(Grade 1B).
B For patients with STEMI undergoing primary PCI, we
recommend administration of IV UFH over no UFH ther-
apy (Grade 1C). The recommended periprocedural dosing
in patients receiving a glycoprotein (GP) IIb/IIIa inhibitor
is 50e70 U/kg (target activated clotting time
[ACT] > 200 s); in patients not receiving a GP IIb/IIIa in-
hibitor, the recommended periprocedural dosing is
60e100 U/kg (target ACT, 250e350 s).
 Low-Molecular-Weight Heparin (Enoxaparin)50
B In patients <75 years of age: 30 mg intravenous bolus
followed 15 min later by 1 mg/kg s.c. every 12 h until
hospital discharge for a maximum of 8 days. The first two
doses should not exceed 100 mg.
B In patients >75 years of age: no intravenous bolus; start
with first subcutaneous dose of 0.75 mg/kg with a
maximum of 75 mg for the first two s.c. doses.
B In patients with creatinine clearance of <30 mL/min,
regardless of age, the subcutaneous doses are given once
every 24 h.
 Fondaparinux50
B 2.5 mg i.v. bolus followed by a subcutaneous dose of
2.5 mg once daily up to 8 days or hospital discharge.
Concomitant administration of heparin and reteplase
 Heparin and reteplase are incompatible when combined in
solution; hence should not be administered simultaneously
in the same intravenous line. If reteplase is to be injected
through an intravenous line containing heparin, a normal
saline or 5% dextrose solution should be flushed through the
line before and after administering the reteplase injection.66
3.2. Concomitant use of antiplatelet drugs
While the initial goal of reperfusion is to restore flow in the
infarct-related artery (IRA) as quickly and completely as
possible, the ultimate goal of reperfusion in STEMI is to
maintain IRA patency and improve myocardial perfusion inthe infarct zone. Despite adequate restoration of flow in the
epicardial IRA, perfusion of the infarct zone may still be
compromised by a combination of microvascular damage and
reperfusion injury. Microvascular damage occurs as a conse-
quence of downstream embolization of platelet microemboli
and thrombi followed by release of substances from activated
platelets that promote occlusion or spasm. Thus, in order to
maintain IRA patency (decreasing thrombus recurrence and
preventing reocclusion) and potentially minimize microvas-
cular damage, adjunctive antiplatelet and antithrombotic
treatments should be included in the management of acute
STEMI, regardless of the reperfusion strategy initially
employed.13
Convincing evidence of the effectiveness of aspirin in
addition to fibrinolysis was demonstrated by the ISIS-2, in
which the benefits of aspirin and streptokinase were seen to
be additive. The first dose of 150e300 mg should be chewed or
given intravenously (though at a lower dose range) and a
lower dose (75e100 mg) given orally daily thereafter.
In the CLopidogrel as Adjunctive Reperfusion Therapye
Thrombolysis In Myocardial Infarction 28 (CLARITY-TIMI 28)
trial, clopidogrel added to aspirin reduced the risk of cardio-
vascular events in patients 75 years of age who had been
treated with fibrinolysis.50
Accordingly, there is a good case for the routine use of
clopidogrel added to aspirin as an adjunct to lytic therapy.
Prasugrel and ticagrelor have not been studied as adjuncts to
fibrinolysis and should not be given.50
ACCP recommends
1. Antiplatelet therapy50
Aspirin
162- to 325-mg loading dose (I A)
81- to 325-mg daily maintenance dose (indefinite) (I A)
81 mg daily is the preferred maintenance dose IIa B
2.P2Y12 receptor inhibitors
Clopidogrel: I A
Age <75 y: 300-mg loading dose
Followed by 75 mg daily for at least 14 d and up to 1 y in
absence of bleeding I A (14 d)
Age >75 y: no loading dose, give 75 mg (I A)
Followed by 75 mg daily for at least 14 d and up to 1 y in
absence of bleeding
3.3. Complications of fibrinolysis
 The main complication of fibrinolytic therapy is bleeding,
with the most dreaded complication being ICH. The dosage
of adjunctive IV UFH, the measured aPTT level, as well as
the timing of aPTT monitoring appear to have a strong
relationship with the risk of ICH19
 Predictors of ICH: age, weight, prior cerebrovascular disease,
diastolic BP, combination alteplase-SK therapy, hyperten-
sion, hypertension  age interaction term, accelerated
alteplase treatment, systolic BP19
 Adjunctive heparin use in the setting of fibrinolytics agents
appears to have a narrow therapeutic window. While the
baseline risk of ICH varies between individual studies, there
appears to be a consistent association between heparin
dosing and risk of ICH.19
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level as well as the timing of APTT monitoring appears to
have a strong relationship with the risk of ICH. Early trials
recommended initial APTT evaluation at 6 h. In contrast,
heparin dose adjustment with 3-h APTT monitoring resul-
ted in the lowest reported ICH rate of 0.64% observed in any
megatrial. When this approach was repeated in the
ASSENT-3 trial, this heparin-dosing regimen resulted in
0.94% ICH rate.19
 Severe bleeding-causing substantial hemodynamic
compromise requiring intervention, and moderate bleeding
as that requiring transfusion but without associated he-
modynamic compromise19
 The most common cause of bleeding may be the use of
coronary revascularization procedures. The most powerful
multivariable predictors of moderate or severe bleeding are
advanced age, lighter body weight, and female sex. These
variables remained the most potent predictors of bleeding
risk even among patients who did not undergo an in-
hospital cardiac procedure.
 The other bleeding complications associated with fibrino-
lysis, usually are only minor (e.g., puncture site bleeding
after PCI).19
 Rates of hemorrhage other than intracranial as reported in
randomized trials of thrombolysis are difficult to interpret
because of varying definitions, different intensities of data
collection and differences in use of invasive revascularisa-
tion procedures. Overall, in the placebo-controlled trials
there is a 2- to 3-fold increased incidence of severe hemor-
rhage after thrombolytic therapy (0.4% among controls vs
1.1% among patients randomized to active treatment).62
 That fibrin specificity is associated with bleeding even after
adjustment for the aPTT level is suggested by a greater
bleeding risk with first generation >second generation
>third generation.193.4. Management of serious bleeding which occurs in a
critical location
(intracranial, gastrointestinal, retroperitoneal, pericardial)
 Any concomitant heparin should be terminated immedi-
ately. Heparin effects can be reversed by protamine
 In addition, the second bolus of reteplase should not be
given if the serious bleeding occurs before it is administered.3.5. Precautions to be taken for bleeding at external sites
(including catheter insertion sites, arterial and venous
puncture sites, cutdown sites, and needle puncture sites)
 Noncompressible arterial puncture must be avoided and
internal jugular and subclavian venous punctures should be
avoided to minimize bleeding from noncompressible sites.
 Should an arterial puncture be necessary during the
administration of reteplase, it is preferable to use an upper
extremity vessel that is accessible to manual compression.
Pressure should be applied for at least 30 min, a pressure
dressing applied, and the puncture site checked frequently
for evidence of bleeding.3.6. Managing complications other than bleeding that
may occur
 Arrhythmias-Manage with standard antiarrhythmic mea-
sures. It is recommended that antiarrhythmic therapy for
bradycardia and/or ventricular irritability be available when
reteplase is administered4. Pharmacoeconomics
Despite the need for the initial investment and the lower
diagnostic accuracy of AMI in the prehospital care group, the
total cost of the hypothetical cohort of patients followed for
one year was lower compared to the inhospital treatment. In
spite of the higher cost of the bolus thrombolytic agent when
compared to SK, the higher effectiveness of the first in the
prehospital environment allows theminimization of the costs
resulting from complications that are secondary to the delay
in the reperfusion of patients with AMI, such as heart failure,
reinfarction and the need for a higher number of high-cost
interventions. The benefits of intervention health, i.e., the
possibility of early reperfusion, can mean a lower cost in the
mid- and long-term, due to the decrease in reinfarction and
morbidity of the chronic ischemic cardiopathy.675. Future trends in thrombolysis
5.1. Telemedicine
“Tele-Medicine (TM) is the use of telecommunication and in-
formation technologies in order to provide clinical health care
at a distance. It helps eliminate distance barriers and can
improve access to medical services that would often not be
consistently available in distant rural communities. It is also
used to save lives in critical care and emergency situations”.
TM may therefore be extremely useful in reducing time of
treatment, especially when time is paramount, such as in
cardiovascular emergencies. When treating patients with
AMI, the time from the onset of symptoms to reperfusion is
crucial for salvaging myocardium; in other words, “time is
muscle”. Shorter time-to-reperfusion is associated with
smaller infarct size and micro-vascular damage and larger
salvaged myocardium.68
Despite many years of medical advances, the time from
symptom onset to thrombolysis has remained at large un-
changed, with a median of 2.5e3 h. A prehospital treatment
strategy when compared with inhospital thrombolysis has
been shown to reduce time to thrombolysis with around 1 h
and inhospital mortality by 17% in a meta-analysis of ran-
domized trials.69
A nation-wide registry of real-life patients showed that
prehospital diagnosis and treatment are associated with
reduced time to thrombolysis by almost 1 h and reduced
adjusted long-term mortality by 30%. Importantly, pre-
hospital diagnosis established by a physician at the hospital
using telemedicine and subsequent Prehospital thrombol-
ysis (PHT) delivered by paramedics in the ambulances
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 5 6 6e5 8 5 583seem as efficient in reducing time delays as physician-
staffed ambulances.69
Prehospital Electrocardiograms (ECGs) may be useful in
improving timeliness of treatments in acute cardiovascular
disease, and TM may play a primary role in allowing any pa-
tient with a suspected cardiovascular emergency to be
examined with prehospital ECG by a cardiologist, wherever
the patient is, either in rural or urban areas.68
A system with paramedics, who transmit a prehospital
ECG using telemedicine to a physician in the hospital for
decision-making and then administrating thrombolysis,
seems as efficient in reducing treatment delay as a system
with physician-staffed ambulances.69
5.2. Nano-thrombolysis
With regard to thrombolytic therapies, significant advance-
ments have been made in order to increase the efficacy of
plasminogen activators. The evolution from fibrin non-
specific to fibrin-specific therapeutics was the first step,
allowing for a decrease in the activation of circulating plas-
minogen. This has been followed by the reengineering of the
PA in order to modulate its blood half life. Recombinant tPA,
which was utilized in this study, is often given as an infusion
over the course of 90 min, as its blood half life is 4e6 min.70
Third generation agents given as a single bolus, may take
20e24 min to clear from the blood, have higher fibrin speci-
ficity, yet still demonstrates similar ICH rates as tPA ofw1% in
AMI patients with 55% of ICH patients dying, and 55% of ICH
survivors possessing residual neurological deficit.
In fact, 20% of IRA fail to reestablish normal coronary flow
following tPA therapy. In addition, another 15 percent of
reperfused arteries will reocclude, leading to larger infarct
size.70
It is therefore vital to develop new thrombolytic agents with
potentially increased efficacy and fibrin specificity, greater
therapeutic windows, and vastly improved safety profiles.70
Nanomaterials are promising modalities for building tar-
geted thrombolytics. For themost part, it is difficult to develop
nanoagents that transverse the blood brain barrier (BBB) in the
absence of permeabilization. This may be due, in part, to the
lack of an endogenous pathway for the particles to translocate
into the brain. Thus, covalent attachment of thrombolytics to
a targeted nanoparticulate delivery vehicle may lead to the
development of agents minimizing the most egregious of side
effects, ICH. Nanomaterials may also extend the circulation
time of PAs, allowing them to be administered as a bolus as
opposed to an infusion, increasing the duration of effect.70
Thus, thedesignofnanoagentswithcomparable therapeutic
efficacy to the free drugs, yet demonstrating superior safety
profiles may provide for the easing of the complications often
associated with PA therapies, particularly intracerebral hemor-
rhage, as nanoagents with minimal BBB permeability can be
utilized to develop targeted thrombolytics.70Conflicts of interest
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